KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2026)

Aquestive Therapeutics has reported Cash from Operations over the past 9 years, most recently at 8469000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 30.51% year-over-year to 8469000.0; the TTM value through Dec 2025 reached 52432000.0, down 46.63%, while the annual FY2025 figure was 52432000.0, 46.63% down from the prior year.
  • Cash from Operations for Q4 2025 was 8469000.0 at Aquestive Therapeutics, up from 12649000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 8816000.0 in Q1 2023 and troughed at 23400000.0 in Q1 2025.
  • A 5-year average of 6868450.0 and a median of 7910500.0 in 2023 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: skyrocketed 204.4% in 2022 and later tumbled 406.18% in 2024.
  • Year by year, Cash from Operations stood at 8061000.0 in 2021, then skyrocketed by 204.4% to 8416000.0 in 2022, then plummeted by 158.72% to 4942000.0 in 2023, then crashed by 31.3% to 6489000.0 in 2024, then tumbled by 30.51% to 8469000.0 in 2025.
  • Business Quant data shows Cash from Operations for AQST at 8469000.0 in Q4 2025, 12649000.0 in Q3 2025, and 7914000.0 in Q2 2025.